^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

MUC1 expression

i
Other names: MUC1, ADMCKD, ADMCKD1, CD227, MCD, MCKD, MCKD1, PEM, PUM, Mucin 1, cell surface associated, Cancer antigen 15-3
Entrez ID:
Related biomarkers:
6d
XIST and MUC1-C form an auto-regulatory pathway in driving cancer progression. (PubMed, Cell Death Dis)
Our results further demonstrate that the MUC1-C/XIST pathway (i) is regulated by TDP-43, (ii) drives stemness-associated genes, and (iii) is necessary for self-renewal capacity. These findings indicate that the MUC1-C/XIST auto-regulatory axis is of importance in cancer progression.
Journal
|
MUC1 (Mucin 1) • MIR21 (MicroRNA 21) • TARDBP (TAR DNA Binding Protein) • METTL3 (Methyltransferase Like 3) • WTAP (WT1 Associated Protein) • XIST (X Inactive Specific Transcript) • YTHDF2 (YTH N6-Methyladenosine RNA Binding Protein 2) • RBM15 (RNA Binding Motif Protein 15)
|
MUC1 expression
16d
MUC1 promotes cervical squamous cell carcinoma through ERK phosphorylation-mediated regulation of ITGA2/ITGA3. (PubMed, BMC Cancer)
Moreover, we designed a combination drug regimen comprising MUC1-siRNA and a novel ERK inhibitor in vivo and found that the combination of these drugs achieved better results in animals with xenografts than did MUC1 alone. Overall, we discovered a novel regulatory pathway, MUC1/ERK/ITGA2/3, in cervical squamous cell carcinoma that may serve as a potential biomarker and therapeutic target in the future.
Journal
|
MUC1 (Mucin 1) • ITGA2 (Integrin Subunit Alpha 2) • ITGA3 (Integrin Subunit Alpha 3)
|
MUC1 expression • MUC1 underexpression
24d
Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=18, Recruiting, Mayo Clinic | Trial completion date: Apr 2025 --> Oct 2025 | Trial primary completion date: Apr 2024 --> Oct 2024
Trial completion date • Trial primary completion date
|
MUC1 (Mucin 1)
|
MUC1 expression
|
cyclophosphamide
1m
Hypoxia-mediated attenuation of EGLN2 inhibition of the NF-κB signaling pathway leads to the formation of a loop between HIF-1α and MUC1-C promoting chemoresistance in bladder cancer. (PubMed, Mol Carcinog)
The IC50 of cells to gemcitabine was determined using the CCK8 assay...Simultaneously, EGLN2-mediated degradation of HIF-1α was reduced. This ultimately led to elevated HIF-1α-mediated downstream gene expression, promoting increased glucose uptake and glycolysis, and ultimately resulting in heightened chemotherapy resistance and malignancy.
Journal
|
MUC1 (Mucin 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
MUC1 expression • HIF1A expression
|
gemcitabine
2ms
Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps (clinicaltrials.gov)
P2, N=110, Active, not recruiting, National Cancer Institute (NCI)
Trial completion date • Metastases
|
MUC1 expression
|
Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine
2ms
The MUC1-HIF-1α signaling axis regulates pancreatic cancer pathogenesis through polyamine metabolism remodeling. (PubMed, Proc Natl Acad Sci U S A)
By utilizing organoid and orthotopic pancreatic cancer mouse models, we observed that targeting SAT1 with pentamidine improved the efficacy of FOLFIRINOX, suggesting that the combination may represent a promising therapeutic strategy against pancreatic cancer. This study provides insights into the interplay between MUC1 and polyamine metabolism, offering potential avenues for the development of treatments against pancreatic cancer.
Journal
|
MUC1 (Mucin 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
MUC1 expression • HIF1A expression
|
5-fluorouracil • irinotecan • leucovorin calcium
3ms
Efficacy of MUC1-targeted CAR-NK cells against human tongue squamous cell carcinoma. (PubMed, Front Immunol)
We observed no weight loss, severe hematological toxicity or NK cell-mediated death in the BNDG mice. The MUC1-targeted CAR-NK cells had significant efficacy against human OTSCC, and their promising therapeutic response warrants further clinical trials.
Journal
|
CD19 (CD19 Molecule) • MUC1 (Mucin 1)
|
CD19 expression • MUC1 expression
3ms
Molecular crosstalk between MUC1 and STAT3 influences the anti-proliferative effect of Napabucasin in epithelial cancers. (PubMed, Sci Rep)
Therefore, high-MUC1 tumors may have a better outcome to Napabucasin therapy. We report how MUC1 regulates STAT3 activity and provide a new perspective on repurposing the STAT3-inhibitor Napabucasin to improve clinical outcome of epithelial cancer treatment.
Journal
|
MUC1 (Mucin 1) • STAT3 (Signal Transducer And Activator Of Transcription 3)
|
MUC1 expression
|
napabucasin (BBI608)
3ms
MUC1-EGFR crosstalk with IL-6 by activating NF-κB and MAPK pathways to regulate the stemness and paclitaxel-resistance of lung adenocarcinoma. (PubMed, Ann Med)
The mRNA-seq showed that knocking down MUC1 affected the gene expression, DEGs mainly enriched in NF-κB and MAPK signalling pathway. MUC1 was highly expressed in A549/TAX cells, and MUC1-EGFR crosstalk with IL-6 may be due to the activation of NF-κB and MAPK pathways, which promote the enrichment of CSCs and lead to paclitaxel resistance.
Journal
|
EGFR (Epidermal growth factor receptor) • IL6 (Interleukin 6) • MUC1 (Mucin 1) • SOX2 • POU5F1 (POU Class 5 Homeobox 1) • NANOG (Nanog Homeobox)
|
MUC1 expression • MUC1 expression + EGFR expression • IL6 expression • POU5F1 expression
|
paclitaxel
3ms
TUMOR MARKERS EXPRESSION LEVELS IN GASTRIC CANCER PATIENT'S PERIPHERAL BLOOD BY RT-PCR ASSESSMENT. (PubMed, Arq Bras Cir Dig)
CK20 and MUC1 expression levels could be assessed by qRT-PCR from total peripheral blood samples of patients with gastric cancer. CK20 levels were correlated to MUC1 levels as well as to tumor size. There was no difference in disease-free survival and overall survival regarding both genetic markers expression in this series.
Journal
|
MUC1 (Mucin 1) • KRT20 (Keratin 20)
|
MUC1 expression
4ms
Mucin-1-Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid Tumors in Immunocompetent Host. (PubMed, J Immunother)
We also report that a single dose of MUC1 CAR T-cell treatment modestly reduced the pancreatic tumor burden in a syngeneic orthotopic model of pancreatic ductal adenocarcinoma given at late stage of an established tumor. Taken together, these findings suggested the further development of tMUC1-targeted CAR T cells as an effective and relatively safe treatment modality for various tMUC1-expressing solid tumors.
Journal • CAR T-Cell Therapy
|
MUC1 (Mucin 1)
|
MUC1 expression
5ms
MUC1-C is a target of salinomycin in inducing ferroptosis of cancer stem cells. (PubMed, Cell Death Discov)
As confirmation of these results, rescue of MUC1-C downregulation with the MUC1-C cytoplasmic domain (i) reversed the suppression of GSR, LRP8 and GPX4 expression, and (ii) attenuated the induction of ferroptosis. These findings identify SAL as a unique small molecule inhibitor of MUC1-C signaling and demonstrate that MUC1-C is an important effector of resistance to ferroptosis.
Journal • Cancer stem
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MUC1 (Mucin 1) • GPX4 (Glutathione Peroxidase 4)
|
MUC1 expression • GPX4 expression
|
salinomycin (HSB-1216)
5ms
Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy. (PubMed, J Cancer)
In recent years, a number of therapeutic strategies targeting MUC1 have been developed and their value for tumor therapy have been demonstrated experimentally. This review summarizes recent findings on the structure of MUC1, its expression in different tumors and its involved mechanism pathways, with emphasis on new progress in cancer therapy which related MUC1 in the past decade and evaluates their therapeutic effect.
Review • Journal • IO biomarker
|
MUC1 (Mucin 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
|
MUC1 expression
5ms
BLV-miR-B1-5p Promotes Staphylococcus aureus Adhesion to Mammary Epithelial Cells by Targeting MUC1. (PubMed, Animals (Basel))
Real-time polymerase chain reaction, immunofluorescence, and dual luciferase reporter assay further confirmed that BLV-miR-B1-5p could target and inhibit the expression of MUC1 in bovine MAC-T cells while interfering with the expression of MUC1 promoted S. aureus adhesion to MAC-T cells. These results indicate that BLV-miR-B1-5p promotes S. aureus adhesion to mammary epithelial cells by targeting MUC1.
Journal
|
MUC1 (Mucin 1)
|
MUC1 expression
5ms
Relationship Between Immunophenotypes, Genetic Profiles, and Clinicopathologic Characteristics in Small Bowel Adenocarcinoma. (PubMed, Am J Surg Pathol)
The SBA immunophenotype correlated with tumor location, biological behavior, and genomic alterations. Our results suggest that the molecular pathway involved in carcinogenesis of gastric-type SBA differs from that of intestinal-type SBA.
Journal
|
MUC1 (Mucin 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • MME (Membrane Metalloendopeptidase) • MUC4 (Mucin 4, Cell Surface Associated) • CDX2 (Caudal Type Homeobox 2) • MUC2 (Mucin 2) • MUC5AC (Mucin 5AC) • MUC6 (Mucin 6)
|
APC mutation • CTNNB1 mutation • MUC1 expression • MUC4 expression • MUC5AC expression
6ms
Role of the cAMP-PKA-NF-κB pathway in Mucin1 over-expression in A549 cells during Respiratory syncytial virus infection. (PubMed, BMC Infect Dis)
dbcAMP and KT5720 had the same effects on MUC1 protein levels in RSV-infected A549 cells. In conclusion, we found that the cAMP-PKA-NF-κB pathway may play a role in the regulation of MUC-1 over-expression during RSV infection.
Journal
|
MUC1 (Mucin 1) • NFKBIA (NFKB Inhibitor Alpha 2)
|
MUC1 expression
6ms
The Role of Mucin Expression in the Diagnosis of Oesophago-Gastric Cancer: A Systematic Literature Review. (PubMed, Cancers (Basel))
Mucin expression varies in OGC; changes may be epigenetic or mutational. Profiling upper GI mucin expression in OGC, with pre-malignant, benign and healthy controls may identify potential early diagnostic biomarkers.
Review • Journal
|
MUC1 (Mucin 1) • MUC2 (Mucin 2) • MUC5AC (Mucin 5AC) • MUC6 (Mucin 6)
|
MUC1 expression • MUC5AC expression
7ms
Pancreatic ductal adenocarcinoma with acinar-to-ductal metaplasia-like cancer cells shows increased cellular proliferation. (PubMed, Pancreatology)
These results indicated that acinar cells may act as the origin of human PDAC, and that their presence may be useful for the stratification of human PDAC to predict prognosis.
Journal
|
MUC1 (Mucin 1) • AGR2 (Anterior gradient 2) • KRT19 (Keratin 19)
|
MUC1 expression • AGR2 expression
7ms
MUC1-C IS A COMMON DRIVER OF ACQUIRED OSIMERTINIB RESISTANCE IN NON-SMALL CELL LUNG CANCER. (PubMed, J Thorac Oncol)
Our findings demonstrate that MUC1-C is a common effector of osimertinib resistance and is a potential target for the treatment of osimertinib resistant NSCLCs.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • MUC1 (Mucin 1)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR T790M • EGFR C797S • MET mutation • MUC1 expression • EGFR H1975
|
Tagrisso (osimertinib)
7ms
MUC1-C INTEGRATES CHRONIC ACTIVATION OF INTERFERON PATHWAYS WITH CHROMATIN REMODELING IN TREATMENT RESISTANCE OF TRIPLE-NEGATIVE BREAST CANCER (SABCS 2023)
In support of these results, targeting MUC1-C in wild-type BRCA1/2 TNBC cells enhanced carboplatin-induced DNA damage and loss of self- renewal capacity. In addition, MUC1-C was necessary for DNA damage resistance, self-renewal and tumorigenicity of olaparib-resistant BRCA1-mutant TNBC cells...As one example, an allogeneic anti-MUC1-C CAR T cell using MAb 3D1 sequences is undergoing Phase I evaluation for the treatment of MUC1-C-expressing cancers (NCT05239143: P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects with Advanced or Metastatic Solid Tumors). In addition, anti-MUC1-C huMAb3D1-MMAE ADCs are under development by the NCI NExT Program for IND-enabling studies and performing early phase clinical trials in patients with TNBC.
BRCA Biomarker • PARP Biomarker • IO biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PBRM1 (Polybromo 1) • MUC1 (Mucin 1) • IDO1 (Indoleamine 2,3-dioxygenase 1) • STING (stimulator of interferon response cGAMP interactor 1) • IRF1 (Interferon Regulatory Factor 1) • STAT1 (Signal Transducer And Activator Of Transcription 1) • IFIH1 (Interferon Induced With Helicase C Domain 1)
|
BRCA1 mutation • BRCA wild-type • PBRM1 mutation • MUC1 expression • IRF1 expression
|
Lynparza (olaparib) • carboplatin • P-MUC1C-ALLO1
7ms
Novel immunotherapy regiment approach for pancreatic ductal adenocarcinoma (PDCA) using human MUC1 transgenic mice (MUC1.tg) model: optimizing conditions for MVA vaccine evaluation (SITC 2023)
These results are consistent with previous researchers4 and will allow the start of the new vaccination regimen (table 2). Conclusions Those are initial data to optimize the conditions for the next experiments with vaccine evaluation associated with adjuvant drugs to understand the mechanisms of protection investigation cellular and antibody immune responses.
Preclinical • PD(L)-1 Biomarker • IO biomarker
|
MUC1 (Mucin 1)
|
PD-L1 expression • MUC1 expression
7ms
The Therapeutic Effects of MUC1-C shRNA@FeO Magnetic Nanoparticles in Alternating Magnetic Fields on Triple-Negative Breast Cancer. (PubMed, Int J Nanomedicine)
In conclusion, we developed MUC1-C shRNA@FeO MNPs with magnetic hyperthermia and gene therapy functions, which have shown satisfactory therapeutic effects on TNBC without significant side effects. This study provides a potential option for the precision treatment of TNBC.
Journal • IO biomarker
|
MUC1 (Mucin 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • GPX4 (Glutathione Peroxidase 4) • FTH1 (Ferritin Heavy Chain 1)
|
MUC1 expression
7ms
Does non-cavity distorting intramural fibroid affect endometrium around the time of embryo implantation? (PubMed, Hum Fertil (Camb))
There was no significant difference in Glycodelin expression in luminal and glandular epithelium, uNK cells density or histological dating results between the paired endometrial samples. In conclusion, it is uncertain whether the altered expression of Mucin1 in luminal epithelium alone may have impact on implantation when other markers are not changed.
Journal
|
MUC1 (Mucin 1)
|
MUC1 expression
8ms
Histologic subtype-based evaluation of recurrence and survival outcomes in patients with adenocarcinoma of the ampulla of Vater. (PubMed, Sci Rep)
In the cohort of 38 patients who received first-line palliative chemotherapy, a diminished median overall survival (OS) was observed in the PB group compared to the intestinal group (10.3 vs. 28.3 months, HR = 2.47; 95% CI, 1.23-4.95; p = 0.025). By integrating histopathologic and molecular criteria, we can identify distinct and clinically relevant histomolecular phenotypes in adenocarcinomas of the ampulla of Vater, which could have considerable impact on existing therapeutic approaches.
Journal
|
MUC1 (Mucin 1) • CDX2 (Caudal Type Homeobox 2) • MUC2 (Mucin 2)
|
MUC1 expression • MUC2 negative
8ms
Immunohistochemical Evaluation of the Expression of Specific Membrane Antigens in Patients with Pancreatic Ductal Adenocarcinoma. (PubMed, Cancers (Basel))
The histological expression of CA 19-9 may predict prognosis. MUC4, MSLN, ANXA10, and GPC-1 are selectively expressed by neoplastic tissue and may represent a potential histological biomarker of disease.
Journal
|
MSLN (Mesothelin) • MUC1 (Mucin 1) • GPC1 (Glypican 1) • ANXA1 (Annexin A1) • MUC4 (Mucin 4, Cell Surface Associated) • ANXA10 (Annexin A10)
|
MUC1 expression • MUC4 expression
8ms
Stepwise progression of invasive mucinous adenocarcinoma based on radiological and biological characteristics. (PubMed, Lung Cancer)
There were no differences in genetic alternations; however, mucin expression pattern was different. Surgical outcomes were different according to the presence of GGO in the solitary type and the presence of CPA in the pneumonic type. These findings suggested a stepwise progression from solitary to pneumonic IMA.
Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • NRG1 (Neuregulin 1) • MUC1 (Mucin 1) • GNAS (GNAS Complex Locus) • MUC6 (Mucin 6)
|
MUC1 expression
8ms
Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma. (PubMed, Lung Cancer)
This is the first study demonstrating KL-6 as a potential novel liquid-based diagnostic and prognostic biomarker in PM.
Journal • IO biomarker
|
MSLN (Mesothelin) • MUC1 (Mucin 1) • KL (Klotho)
|
MUC1 expression
8ms
Tiliroside Combined with Anti-MUC1 Monoclonal Antibody as Promising Anti-Cancer Strategy in AGS Cancer Cells. (PubMed, Int J Mol Sci)
The combined action of anti-MUC1 and tiliroside was more effective in comparison with monotherapy in the case of C1GalT1, ST3GalT1, FUT4, Gal-3, NF-κB, Akt mRNAs, and Tn antigen, as well as sialyl T antigen expression. The results of our study indicate that applied combined therapy may be a promising anti-gastric cancer strategy.
Journal
|
NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • LGALS3 (Galectin 3) • FUT4 (Fucosyltransferase 4)
|
MUC1 expression
8ms
Safety and clinical activity of ruxolitinib combined with carfilzomib and dexamethasone for patients with carfilzomib-refractory multiple myeloma:Rresults from a phase 1 clinical trial. (IMW 2023)
Ruxolitinib may have an acceptable safety profile in combination with carfilzomib at a dose of 10 mg po bid. Despite early encouraging data with 15 mg, the trial could not conclude the safety of this dose. In this proof-of-principle trial, ruxolitinib may have the potential to overcome refractoriness to carfilzomib.
Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker
|
IL6 (Interleukin 6) • MUC1 (Mucin 1) • JAK1 (Janus Kinase 1)
|
PD-L1 expression • MUC1 expression
|
Jakafi (ruxolitinib) • carfilzomib • dexamethasone
8ms
Preclinical • Journal • IO biomarker
|
MUC1 (Mucin 1)
|
MUC1 expression • MUC1 overexpression
9ms
Porphyromonas gingivalis suppresses oral squamous cell carcinoma progression by inhibiting MUC1 expression and remodeling the tumor microenvironment. (PubMed, Mol Oncol)
Flow cytometry analysis showed that P. gingivalis successfully reversed the immunosuppressive TME, thereby suppressing OSCC growth. In summary, the findings of the present study indicated that the rational use of P. gingivalis could serve as a promising therapeutic strategy for OSCC.
Journal
|
MUC1 (Mucin 1)
|
MUC1 expression • CXCL8 expression
9ms
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=430, Recruiting, Daiichi Sankyo, Inc. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
MUC1 (Mucin 1)
|
MUC1 expression
|
DS-3939
9ms
MUC1 promotes lymph node metastasis in esophageal squamous cell carcinoma by downregulating DNAJB6 expression. (PubMed, Environ Toxicol)
This study indicated that MUC1 could promote tumorigenesis and metastasis in ESCC by downregulating DNAJB6 expression through AKT-HSF-1 pathway.
Journal
|
MUC1 (Mucin 1)
|
MUC1 expression • MUC1 overexpression
9ms
The function of long non-coding RNA SNHG11 and its working mechanism in triple-negative breast cancer. (PubMed, Pathol Res Pract)
It was demonstrated that lncRNA SNHG11 promoted TNBC cell malignant behaviors to facilitate TNBC progression. The study is first of its kinds to unravel the potential of lncRNA SNHG11 in relation to TNBC.
Journal
|
MUC1 (Mucin 1) • MIR7 (MicroRNA 7) • SNHG11 (Small Nucleolar RNA Host Gene 11)
|
MUC1 expression • MUC1 elevation
9ms
In vitro characterisation of [Lu]Lu-DOTA-C595 as a novel radioimmunotherapy for MUC1-CE positive pancreatic cancer. (PubMed, EJNMMI Radiopharm Chem)
[Lu]Lu-DOTA-C595 has favourable in vitro characteristics to target and treat MUC1-CE positive PDAC. Further investigations to characterise the in vivo effects and potential value of [Lu]Lu-DOTA-C595 in other MUC1-CE expressing malignancies such as lung, ovarian and colorectal adenocarcinoma are warranted.
Preclinical • Journal • IO biomarker
|
MUC1 (Mucin 1)
|
MUC1 expression • MUC1 overexpression
10ms
Structural and molecular insight into antibody recognition of dynamic neoepitopes in membrane tethered MUC1 of pancreatic cancer cells and secreted exosomes. (PubMed, RSC Chem Biol)
The X-ray structure revealed that SN-131 interacts directly with Neu5Ac and root GalNAc of the ST antigen in addition to the proximal peptide region. Our results demonstrate that targeting O-glycosylated "dynamic neoepitopes" found in the membrane-tethered MUC1 is a promising therapeutic strategy for improving the treatment outcome of patients with pancreatic cancer.
Journal
|
MUC1 (Mucin 1)
|
MUC1 expression
10ms
Identification and comprehensive analysis of epithelial-mesenchymal transition related target genes of miR-222-3p in breast cancer. (PubMed, Front Oncol)
We successfully identify 10 core ETGs of miR-222-3p, some might be useful diagnostic and prognostic biomarkers. The comprehensive analysis of 10 ETGs and miR-222-3p indicated that they might be involved in the development of BC, which might be novel therapeutic targets for the treatment of BC.
Journal • Tumor mutational burden
|
EGFR (Epidermal growth factor receptor) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • IL6 (Interleukin 6) • MUC1 (Mucin 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • BIRC5 (Baculoviral IAP repeat containing 5) • LAMC2 (Laminin subunit gamma 2) • SERPINE1 (Serpin Family E Member 1) • MMP11 (Matrix Metallopeptidase 11) • NRP1 (Neuropilin 1) • MIR222 (MicroRNA 222)
|
TMB-H • EGFR expression • MUC1 expression • BIRC5 expression • NTRK expression
10ms
Glucocorticoids promote lung metastasis of pancreatic cancer cells through enhancing cell adhesion, migration and invasion. (PubMed, Endocr J)
MUC1-PI3K/AKT pathway, ROCK1/2 and MMP3/7 are involved in the promoting effect of GCs on cell migration, invasion and metastasis in pancreatic cancer cells. These results suggest the importance of reducing stress and GCs administration in patients with pancreatic cancer to avoid an increased risk of cancer metastasis.
Journal
|
MUC1 (Mucin 1) • MMP3 (Matrix metallopeptidase 3)
|
MUC1 expression
10ms
Patterns of Abnormal MUC1 Expression in Patients with PSC and Cholangiocarcinoma (ACG 2023)
Archived tissue from 38 patients were obtained: 5 controls, 22 PSC, 5 PSC/cholangiocarcinoma, and 6 sporadic cholangiocarcinoma. Tissue from controls minimally expressed the hypoglycosylated/abnormal form of MUC1, while tissue from patients with PSC demonstrated moderate expression compared to the very high levels expressed in tissue of patients with sporadic cholangiocarcinoma (Figure 1A). Explants of patients with PSC and concomitant cholangiocarcinoma showed moderate expression of the abnormal MUC1, however it is important to note that all 5 patients were treated with chemo/radiation therapy leading to scarring, loss of epithelial cells and regression of their cancer, interfering with accuracy of these results.
Clinical
|
MUC1 (Mucin 1)
|
MUC1 expression • MUC1 overexpression
10ms
Epigenetic deregulation of MLF1 drives intrahepatic cholangiocarcinoma progression through EGFR/AKT and Wnt/β-catenin signaling. (PubMed, Hepatol Commun)
Our results demonstrated that hypermethylation-mediated miR-29c-3p downregulation contributes to MLF1 upregulation in iCCA, which resulted in tumor cells' proliferation and metastasis through comodulating EGFR/AKT and Wnt/β-catenin signalings.
Journal
|
EGFR (Epidermal growth factor receptor) • MUC1 (Mucin 1) • DNMT1 (DNA methyltransferase 1) • KRT19 (Keratin 19) • GSK3B (Glycogen Synthase Kinase 3 Beta) • WNT3 (Wnt Family Member 3)
|
EGFR expression • MUC1 expression
10ms
Clinical Study to Molecularly Profile Filipino Lung Adenocarcinoma (IASLC-WCLC 2023)
Filipino patients with lung adenocarcinoma albeit small in sample size, have remarkable diversity in molecular profile while confirming reported EGFR and ALK values. CTC values were generally low despite being at advanced stages. CD133, KRT19 and MUC1 expression were detected in half of the samples and may find diagnostic and therapeutic utility.
Clinical
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MUC1 (Mucin 1) • KRT19 (Keratin 19)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • ALK positive • ALK mutation • EGFR G719X • EGFR exon 18 mutation • MUC1 expression • CD133 expression • EGFR mutation + ALK mutation